Teva UK Limited Launches Generic Salmeterol (Salmeterol xinafoate) pMDIBy Teva Uk Ltd, PRNE
Thursday, October 6, 2011
CASTLEFORD, England, October 7, 2011 -
We are pleased to announce the first-to-market launch of generic Salmeterol pMDI.
Salmeterol pMDI is a CFC-free inhaler indicated to help prevent:
- Breathing problems caused by asthma including asthma brought on by exercise and asthma at night in adults and adolescents over 12 years of age; and
- Breathing problems caused by other chest diseases known as chronic obstructive pulmonary disease (COPD) or chronic bronchitis in adults
Salmeterol pMDI from Teva UK Limited is available immediately in 25mcg per actuation pressurised inhalation, suspension in a green inhaler.
Kim Innes, Commercial Director at Teva UK Limited, said, “We are delighted to be bringing the first generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”
To find out more about Teva UK Limited, visit www.tevauk.com.
CPE/11/033. Date of preparation: September 2011.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva’s branded businesses focus on neurological, respiratory and women’s health therapeutic areas as well as biologics. Teva’s leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.
For media enquiries, contact the Teva UK Limited Communications team on +44(0)1977-628500, or email firstname.lastname@example.org.
Tags: Castleford, England, October 7, Teva Uk Ltd, United Kingdom